



**Date: 21 November 2018**

**Sydney, Australia**

**ASX: NOX**

**Noxopharm Limited**

ABN 50 608 966  
123

**Registered Office  
and**

**Operational Office:**

Suite 3, Level 4  
828 Pacific Highway  
Gordon NSW 2072  
Australia

**Board of Directors**

**Mr Peter Marks**

Chairman  
Non-Executive  
Director

**Dr Graham Kelly**

Chief Executive  
Officer  
Managing Director

**Dr Ian Dixon**

Non-Executive  
Director

ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

## **NOXOPHARM ANNOUNCES APPOINTMENT OF MR JOHN MOORE AS NON-EXECUTIVE DIRECTOR**

**Sydney, 21 November 2018:** Noxopharm (ASX: NOX) is pleased to announce the appointment of Mr John Moore as a Non-Executive Director to the Noxopharm Board. The appointment of Mr Moore is effective from the conclusion of today's Annual General Meeting.

Mr Moore is a US citizen. He brings to Noxopharm a wealth of experience in the US Venture and Capital Markets, with a particular focus on new and emerging technologies, including the healthcare space.

John currently serves as Chairman of Trialogics, a clinical trial informatics business, as well as Funderbolt, an education finance technology provider. John has been CEO of several tech companies, with several undertaking successful M & A activities and being sold for significant multiples of funds invested. He has also been involved with several highly successful IPOs. In 2002 he was a partner and CEO of Edson Moore Healthcare Ventures which acquired a portfolio of 16 drug delivery investments from Elan Pharmaceuticals for \$148 million.

In addition to his role with Trialogics, John is also a director of Kalyx Properties.

As Noxopharm further establishes itself in the US market, John's expertise and contacts will be of substantial value in helping guide and advance our commercial strategy, especially in the US market.

An Appendix 3x (Initial Director's Interest Notice) will be released to the ASX at the conclusion of the Annual General Meeting.

.....

### **About Noxopharm Group**

The Noxopharm Group includes Noxopharm Ltd, Nyrada Inc, and NoxAsia Ltd with offices in Sydney, New York and Hong Kong. The Group's drug pipeline contains 4 drug candidates: Veyonda<sup>®</sup>, NYX-104, NYX-205, NYX-330. Veyonda<sup>®</sup> is being developed as an enhancer of radiotherapy across a range of cancers being treated with both standard external beam radiotherapy and intravenous radionuclide (<sup>177</sup>lutetium-PSMA-617) therapy; NYX-104 is a neuroprotectant being developed to limit secondary brain damage (glutamate-induced excitotoxicity) following ischaemic stroke and concussion; NYX-205 is an anti-inflammatory being developed for the treatment of peripheral neuropathy associated with diabetes and chemotherapy; NYX-330 is a PCSK9 inhibitor being developed for the treatment of high blood LDL cholesterol levels that fail to respond adequately to statin therapy alone.

**Investor & Corporate Enquiries:**

Prue Kelly

M: 0459 022 445

E: [info@noxopharm.com](mailto:info@noxopharm.com)

[www.noxopharm.com](http://www.noxopharm.com)

**Company Secretary:**

David Franks

T: +61 2 9299 9690

E: [david.franks@automicgroup.com.au](mailto:david.franks@automicgroup.com.au)

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.